e-Therapeutics pioneered the new science of network pharmacology in drug discovery. Scientists at the Company’s Network Pharmacology Centre near Oxford are using its proprietary computational platform to seek novel treatments for biocomplex diseases including cancer and degeneration. The Company has advanced two drugs into clinical trials: ETS2101 is in phase Ib trials for cancer and ETS6103 is in a phase IIb trial for major depressive disorder. e-Therapeutics also has a number of promising preclinical assets targeting a range of diseases. e-Therapeutics has two UK sites, in Oxford and Newcastle-upon-Tyne. The Company is listed on the AIM market of the London Stock Exchange (ticker ETX).

Significant shareholdings

  • Invesco – 84,524,060 (31.99%)
  • Woodford Asset Management – 46,807,479 (17.7%)
  • Aviva – 44,073,702 (16.7%)
  • Henderson Group plc– 26,168,691 (9.89%)
  • Malcolm Young – 20,644,958 (7.8%)
  • Octopus Group – 11,097,658 (4.2%)

Read more shareholder information.